HUTCHMED (NASDAQ:HCM - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a note issued to investors on Thursday.
Separately, HSBC lowered HUTCHMED from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th.
Check Out Our Latest Report on HUTCHMED
HUTCHMED Stock Performance
Shares of HUTCHMED stock traded up $0.13 on Thursday, reaching $13.40. 42,598 shares of the company were exchanged, compared to its average volume of 101,429. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. The company's 50-day moving average is $14.27 and its two-hundred day moving average is $14.98. HUTCHMED has a 1-year low of $11.51 and a 1-year high of $21.50.
Hedge Funds Weigh In On HUTCHMED
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Crossmark Global Holdings Inc. boosted its stake in shares of HUTCHMED by 10.7% during the 4th quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock worth $268,000 after acquiring an additional 1,799 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of HUTCHMED by 99.9% during the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock worth $102,000 after acquiring an additional 3,532 shares in the last quarter. XY Capital Ltd purchased a new stake in shares of HUTCHMED during the fourth quarter worth $673,000. Summit Trail Advisors LLC raised its holdings in shares of HUTCHMED by 14.4% during the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock worth $189,000 after acquiring an additional 1,647 shares in the last quarter. Finally, ABC Arbitrage SA purchased a new stake in shares of HUTCHMED during the fourth quarter worth $500,000. 8.82% of the stock is owned by institutional investors.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Read More
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
